Lanzillo R, et al. – This study ascertained possible immunometabolic biomarkers able to predict the clinical outcome in multiple sclerosis (MS) patients during treatment with interferon (IFN)–beta–1a. In this study, an immunometabolic screening measuring IL–6, soluble–CD40–ligand (sCD40L), leptin and soluble tumor necrosis factor receptor (sTNF-R) at baseline, before starting IFN–beta–1a, was able to predict a poor response to treatment.